bpc-157 thymosin & TB500 (Thymosin Beta 4) TB 500 vs BPC 157:

Early research suggests good safety when administered under medical supervision

References: D

Injection Debate Community discussion reveals ongoing debate about administration routes: Oral/Sublingual Advocates Argue: BPC-157 originates from gastric proteins and works locally in the gut Oral administration is simpler and less intimidating Some users report excellent gut-related results with oral administration The peptide's acid stability supports oral viability Injection Advocates Argue: More consistent systemic absorption Can target injection site near injury location Most research has used injection methods Concerns about degradation even with acid-stable peptides Community Consensus: A general consensus has emerged that: Oral/sublingual may be preferable for gut-related applications Injection may be preferable for localized injuries (tendons, muscles) Some users employ both routes simultaneously Side Effects and Safety Profile Animal Study Safety Data The extensive animal research on BPC-157 has shown a remarkably favorable safety profile [22]: No observed LD50 (lethal dose) has been established, as studies have not found doses causing toxicity No organ toxicity observed at doses far exceeding therapeutic ranges No carcinogenic effects demonstrated No mutagenic effects in testing No reproductive toxicity observed This exceptional safety profile in animal studies is frequently cited, though translation to humans cannot be assumed

In some cases, we may recommend extending the use of BPC-157 for a longer period if needed, especially in cases of severe fractures or complex surgeries

In this study, curative dosing of TPPU (1 mg/kg) did not alter the levels of MDA and GSH

Grant WB